🔮 Better than the Oracle? Our Fair Value found this +42% bagger 5 months before Buffett bought itRead More

South Korea to begin formal review whether to delist Samsung BioLogics

Published 30/11/2018, 07:32
© Reuters.  South Korea to begin formal review whether to delist Samsung BioLogics
0593xq
-
207940
-

SEOUL (Reuters) - South Korea's bourse operator said it will begin a formal review on whether to delist shares of Samsung (LON:0593xq) BioLogics (KS:207940) over alleged violation of accounting rules.

Once the formal review begins, the bourse plans to decide by the end of December whether the company will be delisted or not, the Korea Exchange said in a statement on Friday.

Trading in shares of Samsung BioLogics, the biotech drug arm of South Korea's top conglomerate - Samsung Group, has been suspended since Nov. 14, immediately after the financial regulator said the company had intentionally breached accounting rules ahead of its listing in 2016.

The company has denied any wrongdoing. Earlier this week, it said it had filed an administrative lawsuit against the regulator Financial Services Commission.

During the bourse's review, trading of BioLogics shares will remain suspended.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.